DOI QR코드

DOI QR Code

Clinical Characteristics and Survival Analysis of Breast Cancer Molecular Subtypes with Hepatic Metastases

  • Ge, Qi-Dong (Department of Breast Oncology, Sun Yat-sen University Cancer Center) ;
  • Lv, Ning (Department of Breast Oncology, Sun Yat-sen University Cancer Center) ;
  • Kong, Ya-Nan (Department of Breast Oncology, Sun Yat-sen University Cancer Center) ;
  • Xie, Xin-Hua (Department of Breast Oncology, Sun Yat-sen University Cancer Center) ;
  • He, Ni (State Key Laboratory of Oncology in South China) ;
  • Xie, Xiao-Ming (Department of Breast Oncology, Sun Yat-sen University Cancer Center) ;
  • Wei, Wei-Dong (Department of Breast Oncology, Sun Yat-sen University Cancer Center)
  • Published : 2012.10.31

Abstract

Background: The liver is one of the most common metastatic sites of breast cancer, hepatic metastases developing in 6%-25% of patients with breast cancer and being associated with a poor prognosis. The aim of this study was to analyze the survival and clinical characteristics of patients with hepatic metastases from breast cancer of different molecular subtypes and to investigate the prognostic and predictive factors that effect clinical outcome. Methods: We retrospectively studied the charts of 104 patients with breast cancer hepatic metastases diagnosed at Sun Yat-sen University Cancer Center from December 1990 to June 2009. Subtypes were defined as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) enriched, triple-negative (TN). Prognostic factor correlations with clinical features and treatment approaches were assessed at the diagnosis of hepatic metastases. Results: The median survival time was 16.0 months, and the one-, two- three-, four-, five-year survival rates were 63.5%, 31.7%, 15.6%, 10.8%, and 5.4%, respectively. Median survival periods after hepatic metastases were 19.3 months (luminal A), 13.3 months (luminal B), 18.9 months (HER2-enriched), and 16.1 months (TN, P=0.11). In multivariate analysis, a 2 year-interval from initial diagnosis to hepatic metastasis, treatment with endocrine therapy, and surgery were independent prognostic factors. Endocrine therapy could improve the survival of luminal subtypes (P=0.004) and was a favorable prognostic factor (median survival 23.4 months vs. 13.8 months, respectively, P=0.011). Luminal A group of patients treated with endocrine therapy did significantly better than the Luminal A group of patients treated without endocrine therapy (median survival of 48.9 vs. 13.8 months, P=0.003). Conclusions: Breast cancer subtypes were not associated with survival after hepatic metastases. Endocrine therapy was a significantly favorable treatment for patients with luminal subtype.

References

  1. Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76. https://doi.org/10.1158/1078-0432.CCR-07-1658
  2. Early Breast Cancer Trialists' Collaborative Group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  3. Fan C, Oh DS, Wessels L, et al (2006). Concordance among gene-expression-based predictors for breast cancer. N Engl J Med, 355, 560-9. https://doi.org/10.1056/NEJMoa052933
  4. Harrell JC, Prat A, Parker JS, et al (2012). Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat, 132, 523-35. https://doi.org/10.1007/s10549-011-1619-7
  5. Hoe AL, Royle GT, Taylor I (1991). Breast liver metastases--incidence, diagnosis and outcome. J R Soc Med, 84, 714-6.
  6. Hu Z, Fan C, Oh DS, et al (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7, 96. https://doi.org/10.1186/1471-2164-7-96
  7. Miller KD, Sledge GW Jr (1999). The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am, 13, 415-34. https://doi.org/10.1016/S0889-8588(05)70063-0
  8. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. https://doi.org/10.1158/1078-0432.CCR-04-0220
  9. O'Reilly SM, Richards MA, Rubens RD (1990). Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer, 26, 574-7. https://doi.org/10.1016/0277-5379(90)90080-D
  10. Parker JS, Mullins M, Cheang MC, et al (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160-7. https://doi.org/10.1200/JCO.2008.18.1370
  11. Patanaphan V, Salazar OM, Risco R (1988). Breast cancer: metastatic patterns and their prognosis. South Med J, 81, 1109-12. https://doi.org/10.1097/00007611-198809000-00011
  12. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. https://doi.org/10.1038/35021093
  13. Shibuya K, Mathers CD, Boschi-Pinto C, et al (2002). Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer, 2, 37. https://doi.org/10.1186/1471-2407-2-37
  14. Sinn HP, Helmchen B, Wittekind CH (2010). [TNM classification of breast cancer: changes and comments on the 7th edition]. Pathologe, 31, 361-6. https://doi.org/10.1007/s00292-010-1307-0
  15. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
  16. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-23. https://doi.org/10.1073/pnas.0932692100
  17. Wyld L, Gutteridge E, Pinder SE, et al (2003). Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer, 89, 284-90. https://doi.org/10.1038/sj.bjc.6601038
  18. Zinser JW, Hortobagyi GN, Buzdar AU, et al (1987). Clinical course of breast cancer patients with liver metastases. J Clin Oncol, 5, 773-82.

Cited by

  1. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7113
  2. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes vol.12, pp.9, 2017, https://doi.org/10.1371/journal.pone.0184680
  3. Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results vol.24, pp.2, 2017, https://doi.org/10.1245/s10434-016-5522-7
  4. Pattern of metastatic spread and subcategories of breast cancer vol.295, pp.1, 2017, https://doi.org/10.1007/s00404-016-4225-4
  5. A Model of Dormant-Emergent Metastatic Breast Cancer Progression Enabling Exploration of Biomarker Signatures vol.17, pp.4, 2018, https://doi.org/10.1074/mcp.RA117.000370
  6. Long-term survival and cure model following liver resection for breast cancer metastases vol.170, pp.1, 2018, https://doi.org/10.1007/s10549-018-4714-1